lumiracoxib
Sign in to saveAlso known as COX189, Prexige®, 2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid, COX 189, COX-189, Lumiracoxibum
Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug.
Research
265 papers- Lumiracoxib.Drugs of today (Barcelona, Spain : 1998) · 2007
- Lumiracoxib.Drugs · 2004
- Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.Clinical pharmacokinetics · 2005
- Lumiracoxib in the management of osteoarthritis and acute pain.Expert opinion on pharmacotherapy · 2007
- Single dose oral lumiracoxib for postoperative pain.The Cochrane database of systematic reviews · 2007
via PubMed
~6 min read
Encyclopedic overview
4 sectionsContents
- History
- Withdrawal from market
- References
- External links
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 408580996 | IUPAC_name = {2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid | image = Lumiracoxib.svg | image_class = skin-invert-image | width = 180px
| tradename = Prexige | Drugs.com = | pregnancy_AU = C | legal_status = Rx-only, withdrawn (Australia, New Zealand, Canada, UK, Germany, Austria, Belgium, Cyprus, Brazil) | routes_of_administration = Oral
Excerpted from Wikipedia’s “lumiracoxib” article, available under the CC BY-SA 4.0 licence.